Loading
Corcept Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 19 Mar 2026.
Corcept Therapeutics Inc: what insiders have been doing
This page follows insider dealings at Corcept Therapeutics Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Menlo Park, United States. The group dates from 1998. From 18 October 2025 to 18 October 2026, the disclosure feed for Corcept Therapeutics Inc logged 216 filings by 20 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €2.2M) and 92 sales (9 insiders, €70.9M). No amount is published for 7 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants. Biggest ticket of the year: €9.3M, sold by Mahoney David l and made public on 20 August 2026 (0.084% of market cap).
The clock since the last published purchase (19 March 2026) now reads 213 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 216 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at 2 purchases and 121 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 761.4 m USD and net income of 99.7 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
449
Thresholds
n/a
Buy Volume
€3M
2 ops. · all time
Sell Volume
€86M
121 ops. · all time
Who traded when
BuySaleMokari Atabak22 sales
Sean Maduck18 sales
Belanoff Joseph K16 sales
James N. Wilson15 sales
Roberto Wandenkolk Vieira11 sales
Guyer William8 sales
+5 other insiders
Since the insiders bought
- +130.7%Entry US$34.64 · Close at T+90 US$79.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Corcept Therapeutics Inc Buy (bullish), based on 5 analysts. Average price target: US$141.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,814 of 24,148 companies
60.3
score / 100
Value41
Quality80
FCF yld1.1%
Earn yld0.8%
EV/EBITDA·
ROE8.2%
Gross mgn98%
Net mgn13%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$115.63
Analyst consensus
5 analystsBuy
US$50.00Target US$141.00(+22%)US$165.00
Income statement
RevenueUS$761.4M
Gross profitUS$748.4M98% margin
EBITDAUS$46.7M6% margin
Net incomeUS$98.2M6.6% margin
Valuation
PER (trailing)257.0x
PER (forward)26.3x
P/Book17.7x
Beta0.45
Balance sheet & cash
Market capUS$12.5B
Total debtUS$6.1M
Free Cash FlowUS$141.8M
Debt / Equity1%
Profitability & ownership
ROE8.2%
ROA0.5%
% insiders11.5%
% institutions76.9%
Last declaration on 16 October 2026
Declarations449 total
3,046 shares@ US$115.38950.0028% mcap15.8% of flowCommon StockSEC:0001193125-26-424350:1
300 shares@ US$116.29670.0003% mcap1.6% of flowCommon StockSEC:0001193125-26-424350:2
6,654 shares@ US$114.47510.0061% mcap34.1% of flowCommon StockSEC:0001193125-26-424350:0
2,086 shares@ US$115.72980.0019% mcap2.8% of flowCommon StockSEC:0001193125-26-414688:2
8,333 shares@ US$21.630.0014% mcap2.1% of flowCommon StockSEC:0001193125-26-414688:0
1,100 shares@ US$114.52050.0010% mcap1.4% of flowCommon StockSEC:0001193125-26-414688:1
5,147 shares@ US$116.5850.0048% mcap6.9% of flowCommon StockSEC:0001193125-26-414688:3
810 shares@ US$13.560.0001% mcap0.2% of flowCommon StockSEC:0001193125-26-414684:0
810 shares@ US$115.39850.0007% mcap1.5% of flowCommon StockSEC:0001193125-26-414684:1
3,357 shares@ US$13.560.0004% mcap0.7% of flowCommon StockSEC:0001193125-26-414684:2
5,833 shares@ US$19.260.0009% mcap1.8% of flowCommon StockSEC:0001193125-26-414684:3
4,446 shares@ US$115.6970.0041% mcap8.1% of flowCommon StockSEC:0001193125-26-414684:4
4,744 shares@ US$116.54070.0044% mcap8.8% of flowCommon StockSEC:0001193125-26-414684:5
413 shares@ US$8.270.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-414674:0
413 shares@ US$115.53730.0004% mcap0.1% of flowCommon StockSEC:0001193125-26-414674:1
24,587 shares@ US$8.270.0016% mcap0.5% of flowCommon StockSEC:0001193125-26-414674:2
15,843 shares@ US$116.12330.015% mcap4.6% of flowCommon StockSEC:0001193125-26-414674:3
8,744 shares@ US$116.55340.0082% mcap2.5% of flowCommon StockSEC:0001193125-26-414674:4
10,000 shares@ US$115.230.0091% mcap87.0% of flowcommonSEC144:0001973251-26-000038
5,000 shares0Common StockSEC:0001193125-26-405402:2
17,100 shares0Common StockSEC:0001193125-26-405402:0
5,000 shares0Common StockSEC:0001193125-26-405402:1
17,493 shares@ US$8.270.0011% mcap2.1% of flowCommon StockSEC:0001193125-26-395827:0
296 shares@ US$100.820.0002% mcap0.4% of flowCommon StockSEC:0001193125-26-395837:0
6,800 shares@ US$110.26980.0059% mcap7.6% of flowCommon StockSEC:0001193125-26-393124:0
25 of 449 declarations
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a commercial-stage biopharmaceutical company headquartered in Redwood City, California, United States. Founded in May 1998 and incorporated in Delaware, the company was built around a focused scientific thesis: modulating cortisol and the glucocorticoid receptor to address serious endocrine and oncology disorders. For international investors, Corcept is best understood as a specialty healthcare name with a hybrid profile: it has an existing commercial product base, but it also retains meaningful development-stage upside tied to clinical and regulatory milestones.
The company’s legacy franchise is Korlym® (mifepristone), which Corcept describes as the first FDA-approved medicine for endogenous Cushing’s syndrome. Korlym established the firm’s commercial platform and remains central to its endocrinology business. Corcept’s broader pipeline is anchored by relacorilant, a selective glucocorticoid receptor antagonist designed to exploit the biology of cortisol in multiple disease settings. In 2026, Corcept achieved a major strategic inflection point when the FDA approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. That approval materially broadens the company’s addressable market beyond Cushing’s syndrome and gives Corcept an approved oncology product alongside its endocrine franchise.
Read moreShow less
From a competitive standpoint, Corcept occupies a differentiated niche rather than competing as a broad-based pharma company. Its advantage lies in deep expertise in cortisol modulation, a therapeutic mechanism that can support both commercial durability and pipeline expansion if clinical data continue to validate the platform. At the same time, the company remains highly dependent on a small number of programs, which makes it sensitive to trial outcomes, regulatory timing, label scope, reimbursement dynamics, and post-approval execution. The concentration risk is offset, however, by the potential for relacorilant to become a meaningful second growth engine.
Operationally, Corcept is primarily US-centric, with its commercial, research, and regulatory activities centered in the United States, while the oncology opportunity is also being developed for broader international reach. Recent highlights include the FDA filing and subsequent approval path for relacorilant in ovarian cancer, the continuing FDA review of relacorilant for hypercortisolism/Cushing’s syndrome, and positive clinical data supporting the broader cortisol-modulation thesis. In short, Corcept on the NASDAQ in the United States remains a catalyst-driven healthcare stock where valuation is likely to be driven by product adoption, label expansion, and execution across a focused pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
